Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
Year: 2020
Type: article
Study design: Observational Study
Abstract: CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell aplasia and hypogammaglobulinemia are common toxicities predisposing these patients to infections. We analyzed 60 patients with DLBCL treated with FDA-approved CD19 CAR T cells and report the incidence, risk factors, and management of infections during the first year after treatment. A total of 101 infectious events were observed, including 25 mild, 51 moderate, 23 severe, 1 life-threatening, and 1 fatal infection. Bacteria were the most common causative pathogens. The cumulative incidence of overall, bacterial, severe bacterial, viral, and fungal infection at 1 year were 63.3%, 57.2%, 29.6%, 44.7%, and 4%, respectively. In multivariate analyses, the use of systemic corticosteroids for the management of CRS or ICANS was associated with an increased risk of infections and prolonged admission. Impaired performance status and history of infections within 30 days before CAR T cell therapy was a risk factor for severe bacterial infection. In conclusion, infections were common within the first 60 days after CAR T cell therapy, however, they were not associated with an increased risk of death.
Source: Blood Cancer Journal
Authors: Kitsada Wudhikarn, M. Lia Palomba, Martina Pennisi, Marta Garcia-Recio, Jessica R. Flynn, Sean M. Devlin, Aishat Afuye, Mari Lynne Silverberg, Molly A. Maloy, Gunjan L. Shah, Michael Scordo, Parastoo B. Dahi, Craig S. Sauter, Connie L. Batlevi, Bianca D. Santomasso, Elena Mead, Susan K. Seo, Miguel-Angel Perales
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: CD19 CAR T-cell therapy, diffuse large B-cell lymphoma, infection incidence, bacterial infection, viral infection, fungal infection, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, systemic corticosteroids, B-cell aplasia, hypogammaglobulinemia, risk factors, performance status
Open Access status: gold
Estimated APC paid: $4,580
Funders: U.S. Department of Health and Human Services, Amgen, Bristol-Myers Squibb, Sanofi, American-Italian Cancer Foundation, Gilead Sciences, Spectrum Pharmaceuticals, Celgene, Memorial Sloan-Kettering Cancer Center, Parker Institute for Cancer Immunotherapy, American Society for Transplantation and Cellular Therapy, Angiocrine Bioscience, Incyte, Omeros Corporation, Servier, National Institutes of Health, Juno Therapeutics, National Cancer Institute
OpenAlex ID: W3046970338
